Transduction of mobilized peripheral blood CD34+ cells with the glucocerebrosidase cDNA
- PMID: 7584082
Transduction of mobilized peripheral blood CD34+ cells with the glucocerebrosidase cDNA
Abstract
Gaucher disease (GD), the most common human lysosomal storage disorder, results from a genetic deficiency of the enzyme glucocerebrosidase (GC). The cloning of human GC cDNA, the benefits of allogeneic bone marrow transplantation and the success of enzyme replacement therapy support the feasibility of gene therapy as an approach to a cure for GD. We report the transfer of the GC gene to mobilized human peripheral blood (PB) CD34+ cells obtained from patients primed with granulocyte colony-stimulating factor and/or chemotherapy. A tenfold enrichment of CD34+ cells was achieved using an avidin-biotin immunoadsorption technique. Prestimulation of the CD34+ cells with cytokines, followed by infection for 5 days with a supernatant containing the MFG-GC retroviral vector, resulted in enzyme activity up to 2.5-times greater than non-infected and lac-Z infected controls. Southern blot hybridization of DNA from these cells demonstrated a transduction efficiency of 10-30%. These studies show that the GC gene is transferred efficiently to mobilized PB CD34+ cells by the MFG-GC retroviral vector and results in expression of enzyme activity in the population of cells capable of bone marrow reconstitution. These results advance the development of gene therapy for GD.
Similar articles
-
Cytokine mobilization of peripheral blood stem cells in patients with Gaucher disease with a view to gene therapy.Exp Hematol. 1995 Dec;23(14):1633-41. Exp Hematol. 1995. PMID: 8542958 Clinical Trial.
-
Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol.Exp Hematol. 1994 Feb;22(2):223-30. Exp Hematol. 1994. PMID: 8299741
-
Transduction of CD34+ enriched cord blood and Gaucher bone marrow cells by a retroviral vector carrying the glucocerebrosidase gene.Gene Ther. 1994 May;1(3):176-84. Gene Ther. 1994. PMID: 7584079
-
[Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].J Soc Biol. 2002;196(2):175-81. J Soc Biol. 2002. PMID: 12360746 Review. French.
-
Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. Curr Opin Investig Drugs. 2010. PMID: 20336596 Review.
Cited by
-
Genetic engineering: moral aspects and control of practice.J Assist Reprod Genet. 1997 Jul;14(6):297-316. doi: 10.1007/BF02765833. J Assist Reprod Genet. 1997. PMID: 9226508 Free PMC article. Review.
-
Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase.Protein Sci. 1995 Apr;4(4):756-64. doi: 10.1002/pro.5560040415. Protein Sci. 1995. PMID: 7613473 Free PMC article.
-
Position of the sulfhydryl group and the disulfide bonds of human glucocerebrosidase.J Protein Chem. 1995 Apr;14(3):127-37. doi: 10.1007/BF01980324. J Protein Chem. 1995. PMID: 7576080
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous